Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 77

Sort by

Sort Order Select

Journal Articles

A 14q32.31 Genomic-Imprinted DLK1-DIO3 microrna promotes Leukemogenesis By Inducing Stem Cell Quiescence and Inhibiting NK Cell Anti-Cancer Immunity

Blood (2019) 134 (Supplement_1): 4141.

https://doi.org/10.1182/blood-2019-131113

Published: 2019

Journal Articles

PP2A Activators Enhance Efficacy of FLT3 Inhibitors in FLT3-ITD Acute Myeloid Leukemia Cells through AKT Inactivation-Dependent Pim-1 and c-Myc Proteasomal Degradation

Mario Scarpa, PhD, Prerna Singh, MS, Shivani Kapoor, MS, Jonelle K. Lee, MS, Sandrine Niyongere, MD, Goutham Narla, MD PhD, Danilo Perrotti, MD PhD, Maria R. Baer, MD

Blood (2019) 134 (Supplement_1): 1276.

https://doi.org/10.1182/blood-2019-129011

Published: 2019

Journal Articles

Concurrent FLT3 Inhibitor and PP2A Activating Drug Treatment Induces Synergistic Cytotoxicity in Acute Myeloid Leukemia Cells with FLT3 Internal Tandem Duplication through Proteasomal Degradation of Pim-1 and c-Myc

Mario Scarpa, PhD, Shivani Kapoor, MS, Danilo Perrotti, MD PhD, Maria R. Baer, MD

Blood (2018) 132 (Supplement 1): 3951.

https://doi.org/10.1182/blood-2018-99-117609

Published: 2018

Journal Articles

The Bone Marrow Niche Uses Mir-300 As a Biological Rheostat to Selectively Control Stem Cell-Driven Malignant Hematopoiesis and Innate Anti-Cancer Immunity

Blood (2017) 130 (Supplement 1): 45.

https://doi.org/10.1182/blood.V130.Suppl_1.45.45

Published: 2017

Journal Articles

Twisting IL-1 signaling to kill CML stem cells

Lorenzo Stramucci, Danilo Perrotti

Blood (2016) 128 (23): 2592–2593.

https://doi.org/10.1182/blood-2016-10-741009

Published: 2016

Journal Articles

Potential Targeting Ph + Acute Lymphoblastic Leukemia Stem and Progenitor Cells By Modulating the CIP2A-SET-SETBP1 -Mediated Suppression of PP2A Activity

Justine Yu, B.S., Giovannino Silvestri, PhD, Lorenzo Stramucci, PhD, Masashi Sanada, MD PhD, Tomoyuki Yamaguchi, PhD, Yang Du, PhD, Jukka Westermarck, MD PhD, Michael A. Caligiuri, MD, Ramiro Garzon, MD, Dragana Milojkovic, MD, Jane F. Apperley, MD, Denis-Claude Roy, MD, Guido Marcucci, MD, Bruno Calabretta, MD PhD, Maria R. Baer, MD, Rossana Trotta, PhD, Danilo Perrotti, MD PhD

Blood (2016) 128 (22): 2909.

https://doi.org/10.1182/blood.V128.22.2909.2909

Published: 2016

Journal Articles

Concurrent Inhibition of Pim-1 and FLT3 Kinases in FLT3-ITD Acute Myeloid Leukemia Post-Translationally Downregulates the Anti-Apoptotic Protein Mcl-1 through Downregulation of the Mcl-1 Deubiquitinase USP9X

Patrick R. Baldwin, PhD, Shivani Kapoor, B.S., Karthika Natarajan, PhD, Rossana Trotta, PhD, Adriana Tron, PhD, Dennis Huszar, PhD, Eduardo Davila, PhD, Danilo Perrotti, MD PhD, Maria R. Baer, MD

Blood (2016) 128 (22): 35.

https://doi.org/10.1182/blood.V128.22.35.35

Published: 2016

Journal Articles

Patients with Chronic Myeloid Leukemia Show Different Modulation of MYB-Dependent Oncogenic Pathway in the Course of Hematopoietic Differentiation upon Sensitivity to the TKI Treatment

Klara Srutova, Nikola Curik, Koblihova Jitka, Filipp Savvulidi, Hana Klamova, Danilo Perrotti, Tomas Stopka, Katerina Machova Polakova

Blood (2015) 126 (23): 1243.

https://doi.org/10.1182/blood.V126.23.1243.1243

Published: 2015

Journal Articles

Knockdown (KD) of Mir-126 Expression Enhances Tyrosine Kinase Inhibitor (TKI)-Mediated Targeting of Chronic Myelogenous Leukemia (CML) Stem Cells

Bin Zhang, PhD, Ling Li, PhD, Ching-Cheng Chen, PhD, Anthony S. Stein, MD, Haris Ali, MD, David S. Snyder, MD, Allen Lin, Adrienne Dorrance, PhD, Piotr Swiderski, PhD, Ravi Bhatia, MD, Danilo Perrotti, MD PhD, Stephen J. Forman, MD, Ya-Huei Kuo, PhD, Marcin Kortylewski, PhD, Guido Marcucci, MD

Blood (2015) 126 (23): 51.

https://doi.org/10.1182/blood.V126.23.51.51

Published: 2015

Journal Articles

Role of the MSC-Derived Exosomal and Endogenous JAK2-SET/PP2A-Beta Catenin-Modulator Mir-300 in Leukemic Stem/Progenitor Proliferation and Survival in CML

Blood (2015) 126 (23): 53.

https://doi.org/10.1182/blood.V126.23.53.53

Published: 2015

Journal Articles

A “RANning” leap with “XPOrt” into TKI resistance

Feyruz Rassool, Danilo Perrotti

Blood (2015) 125 (11): 1686–1688.

https://doi.org/10.1182/blood-2015-01-622217

Published: 2015

Journal Articles

The Pim Kinase Inhibitor AZD1208 Enhances Apoptosis Induction By Clinically Active FLT3 Inhibitors in FLT3-ITD Acute Myeloid Leukemia Cells in Vitro and in Vivo through Synergistic Downregulation of Mcl-1 and of Bcl-xL

Karthika Natarajan, PhD, Trevor J Mathias, MS, Kshama A Doshi, MS, Adriana E Tron, PhD, Manfred Kraus, PhD, Rossana Trotta, PhD, Danilo Perrotti, MD PhD, Dennis Huszar, PhD, Maria R Baer, MD

Blood (2014) 124 (21): 3601.

https://doi.org/10.1182/blood.V124.21.3601.3601

Published: 2014

Journal Articles

MiR-300 Acts As a Tumor Supressor in Ph+ Progenitors By Modulating the JAK2-SET/PP2A/β-Catenin Interplay

Giovannino Silvestri, PhD, Justin Ellis, Lorenzo Stramucci, PhD, Jason G Harb, PhD, Paolo Neviani, PhD, Guido Marcucci, MD, Denis-Claude Roy, MD, Peter Hokland, MD DMSc, Dragana Milojkovic, Alistair Reid, Jane F. Apperley, Ferenc M Livak, PhD, Maria R. Baer, MD, Rossana Trotta, PhD, Danilo Perrotti, MD PhD

Blood (2014) 124 (21): 4529.

https://doi.org/10.1182/blood.V124.21.4529.4529

Published: 2014

Journal Articles

Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cells

Amy M. Cook, Liang Li, Yinwei Ho, Allen Lin, Ling Li, Anthony Stein, Stephen Forman, Danilo Perrotti, Richard Jove, Ravi Bhatia

Blood (2014) 123 (18): 2826–2837.

https://doi.org/10.1182/blood-2013-05-505735

Published: 2014

Includes: Supplemental data

Journal Articles

Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph + leukemias

Blood (2013) 122 (17): 3034–3044.

https://doi.org/10.1182/blood-2013-04-495374

Published: 2013

Includes: Supplemental data

Journal Articles

Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies

Blood (2013) 122 (11): 1923–1934.

https://doi.org/10.1182/blood-2013-03-492181

Published: 2013

Includes: Supplemental data

Journal Articles

Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia

Blood (2013) 121 (1): 159–169.

https://doi.org/10.1182/blood-2012-05-428573

Published: 2013

Includes: Supplemental data

Journal Articles

Therapeutic Targeting of the RAS-Pathway by Synthetic Mir-181a Nanoparticles in Acute Myeloid Leukemia (AML).

Blood (2012) 120 (21): 2422.

https://doi.org/10.1182/blood.V120.21.2422.2422

Published: 2012

Journal Articles

Anti-Leukemic Activity of the CRM1 Inhibitor KPT-330 in Advanced CML and Ph+ ALL

Christopher J Walker, Joshua J Oaks, Ramasamy Santhanam, Ph.D, Paolo Neviani, Ph.D, Jason G Harb, Ph.D, Gregory Ferenchak, Justin Ellis, Guido Marcucci, MD, Yosef Landesman, PhD, Sharon Shacham, PhD MBA, Michael Kauffman, MD, PhD, Danilo Perrotti, MD, Ph.D

Blood (2012) 120 (21): 35.

https://doi.org/10.1182/blood.V120.21.35.35

Published: 2012

Journal Articles

SPARC contributes to Leukemia Growth and Aggressive Disease in Acute Myeloid Leukemia (AML)

Blood (2012) 120 (21): 773.

https://doi.org/10.1182/blood.V120.21.773.773

Published: 2012

NARROW

A 14q32.31 Genomic-Imprinted DLK1-DIO3 microrna promotes Leukemogenesis By Inducing Stem Cell Quiescence and Inhibiting NK Cell Anti-Cancer Immunity

PP2A Activators Enhance Efficacy of FLT3 Inhibitors in FLT3-ITD Acute Myeloid Leukemia Cells through AKT Inactivation-Dependent Pim-1 and c-Myc Proteasomal Degradation

Concurrent FLT3 Inhibitor and PP2A Activating Drug Treatment Induces Synergistic Cytotoxicity in Acute Myeloid Leukemia Cells with FLT3 Internal Tandem Duplication through Proteasomal Degradation of Pim-1 and c-Myc

The Bone Marrow Niche Uses Mir-300 As a Biological Rheostat to Selectively Control Stem Cell-Driven Malignant Hematopoiesis and Innate Anti-Cancer Immunity

Twisting IL-1 signaling to kill CML stem cells

Potential Targeting Ph + Acute Lymphoblastic Leukemia Stem and Progenitor Cells By Modulating the CIP2A-SET-SETBP1 -Mediated Suppression of PP2A Activity

Concurrent Inhibition of Pim-1 and FLT3 Kinases in FLT3-ITD Acute Myeloid Leukemia Post-Translationally Downregulates the Anti-Apoptotic Protein Mcl-1 through Downregulation of the Mcl-1 Deubiquitinase USP9X

Patients with Chronic Myeloid Leukemia Show Different Modulation of MYB-Dependent Oncogenic Pathway in the Course of Hematopoietic Differentiation upon Sensitivity to the TKI Treatment

Knockdown (KD) of Mir-126 Expression Enhances Tyrosine Kinase Inhibitor (TKI)-Mediated Targeting of Chronic Myelogenous Leukemia (CML) Stem Cells

Role of the MSC-Derived Exosomal and Endogenous JAK2-SET/PP2A-Beta Catenin-Modulator Mir-300 in Leukemic Stem/Progenitor Proliferation and Survival in CML

A “RANning” leap with “XPOrt” into TKI resistance

The Pim Kinase Inhibitor AZD1208 Enhances Apoptosis Induction By Clinically Active FLT3 Inhibitors in FLT3-ITD Acute Myeloid Leukemia Cells in Vitro and in Vivo through Synergistic Downregulation of Mcl-1 and of Bcl-xL

MiR-300 Acts As a Tumor Supressor in Ph+ Progenitors By Modulating the JAK2-SET/PP2A/β-Catenin Interplay

Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cells

Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph + leukemias

Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies

Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia

Therapeutic Targeting of the RAS-Pathway by Synthetic Mir-181a Nanoparticles in Acute Myeloid Leukemia (AML).

Anti-Leukemic Activity of the CRM1 Inhibitor KPT-330 in Advanced CML and Ph+ ALL

SPARC contributes to Leukemia Growth and Aggressive Disease in Acute Myeloid Leukemia (AML)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only